Efecto de Combigan® versus placebo en el flujo sanguíneo ocular en pacientes hipertensos oculares

espanolProposito: Estudiar los cambios hemodinamicos retrobulbares mediante ecografia doppler color, en pacientes hipertensos oculares (HTO) en tratamiento con Combigan® versus placebo. Metodo: Treinta pacientes randomizados en 2 grupos paralelos fueron incluidos en un estudio prospectivo y a doble ciego; quince de ellos en tratamiento con Combigan® y quince en tratamiento con placebo, durante un periodo de 3 meses. Se obtuvieron medidas de la presion intraocular (PIO) y del flujo sanguineo a nivel de la arteria central de la retina (ACR) y la arteria oftamica en el momento basal y a los 3 meses. Resultados: Combigan® redujo significativamente la PIO tras tres meses de tratamiento (p=0,001). Los parametros hemodinamicos basales fueron similares entre los grupos placebo y tratamiento. Los pacientes tratados con Combigan® mostraron un descenso estadisticamente significativo del indice de resistencia de la ACR (p=0,007). Conclusiones: Los pacientes tratados durante 3. meses con Combigan® mostraron un descenso estadisticamente significativo del indice de resistenciade la ACR que podria explicarse por el descenso de PIO. EnglishPurpose: This study was undertaken to compare the ocular haemodynamic effects of Combigan® versus placebo in patients with ocular hypertension (OHT). Methods: Thirty patients with OHT were included in a controlled, randomised, double blind study in two parallel groups; 15 were randomised to receive Combigan® and 15 to receive placebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurements of the ophthalmic artery (OA) and central retinal artery (CRA) were taken using colour Doppler imaging (CDI) ultrasound, concurrently with intraocular pressure (IOP). Results: Combigan® significantly reduced IOP after 3 months of treatment (P = 0.001), whereas placebo showed no significant change in IOP. The baseline haemodynamic parameters were similar between treatment and placebo groups. Patients treated with Combigan® showed a statistically significant decrease in CRA resistive index (P = 0.007). Conclusions: Patients treated for 3 months with Combigan® showed a significant decrease of CRA resistive index that could be explained by the decrease in IOP.